Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255007634> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2255007634 endingPage "637" @default.
- W2255007634 startingPage "630" @default.
- W2255007634 abstract "Patients older than 1 year with stage IV neuroblastoma who fail to achieve complete remission (CRem) have a particularly poor long-term prognosis. In an attempt to improve the outcome of these refractory patients, we tested a new drug combination.Twenty-nine children with advanced neuroblastoma (27 stage IV and two stage III) were entered onto this phase II study. All were refractory to conventional chemotherapy and had measurable disease at the time of the trial. The regimen was a combination of high-dose cyclophosphamide (2 g/m2/d) on days 2, 3, and 4, and etoposide (VP16; 50 mg/m2/d) by continuous intravenous (IV) infusion on days 1 to 5. A pharmacokinetic study of VP16 was conducted in eight patients to determine whether the goal of persistent plasma levels between 1 and 5 micrograms/mL was achieved.Patients received a median of two courses, for a total of 58 courses. The median interval between each course was 32 days. In the 28 assessable patients, the overall response rate was 43%, with one CRem and 11 partial remissions (PRems). No life-threatening complication was observed in these heavily pretreated patients. The median duration of neutropenia (< 5 x 10(9)/L) was 14 days, and that of thrombocytopenia (< 50 x 10(9)/L) was 11 days. The overall incidence of sepsis was 27%. Gastrointestinal toxicity was frequent, but mild. Electrolyte disturbance with antidiuretic hormone (ADH)-like syndrome occurred in eight courses, but resolved rapidly. Grade > or = 2 hemorrhagic cystitis was observed in three courses. No cardiac toxicity was observed. There were no treatment-related deaths. Pharmacokinetic analysis showed that mean steady-state plasma levels (Css) of VP16 were greater than 1 microgram/mL during all the courses.This new drug combination appears to be effective in advanced neuroblastoma. Its toxicity remains manageable, with no life-threatening complications. Further evaluation in patients with less-advanced disease is warranted." @default.
- W2255007634 created "2016-06-24" @default.
- W2255007634 creator A5012292266 @default.
- W2255007634 creator A5027448217 @default.
- W2255007634 creator A5036592214 @default.
- W2255007634 creator A5047237285 @default.
- W2255007634 creator A5049325108 @default.
- W2255007634 creator A5054047613 @default.
- W2255007634 creator A5066708720 @default.
- W2255007634 creator A5067202962 @default.
- W2255007634 creator A5078096691 @default.
- W2255007634 creator A5088598951 @default.
- W2255007634 date "1993-04-01" @default.
- W2255007634 modified "2023-09-26" @default.
- W2255007634 title "Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique." @default.
- W2255007634 doi "https://doi.org/10.1200/jco.1993.11.4.630" @default.
- W2255007634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8478658" @default.
- W2255007634 hasPublicationYear "1993" @default.
- W2255007634 type Work @default.
- W2255007634 sameAs 2255007634 @default.
- W2255007634 citedByCount "30" @default.
- W2255007634 countsByYear W22550076342012 @default.
- W2255007634 countsByYear W22550076342019 @default.
- W2255007634 crossrefType "journal-article" @default.
- W2255007634 hasAuthorship W2255007634A5012292266 @default.
- W2255007634 hasAuthorship W2255007634A5027448217 @default.
- W2255007634 hasAuthorship W2255007634A5036592214 @default.
- W2255007634 hasAuthorship W2255007634A5047237285 @default.
- W2255007634 hasAuthorship W2255007634A5049325108 @default.
- W2255007634 hasAuthorship W2255007634A5054047613 @default.
- W2255007634 hasAuthorship W2255007634A5066708720 @default.
- W2255007634 hasAuthorship W2255007634A5067202962 @default.
- W2255007634 hasAuthorship W2255007634A5078096691 @default.
- W2255007634 hasAuthorship W2255007634A5088598951 @default.
- W2255007634 hasConcept C121332964 @default.
- W2255007634 hasConcept C126322002 @default.
- W2255007634 hasConcept C141071460 @default.
- W2255007634 hasConcept C142424586 @default.
- W2255007634 hasConcept C2776694085 @default.
- W2255007634 hasConcept C2776755627 @default.
- W2255007634 hasConcept C2777063308 @default.
- W2255007634 hasConcept C2777600175 @default.
- W2255007634 hasConcept C2778119113 @default.
- W2255007634 hasConcept C2778384902 @default.
- W2255007634 hasConcept C2778850193 @default.
- W2255007634 hasConcept C2781413609 @default.
- W2255007634 hasConcept C29730261 @default.
- W2255007634 hasConcept C71924100 @default.
- W2255007634 hasConcept C87355193 @default.
- W2255007634 hasConcept C90924648 @default.
- W2255007634 hasConceptScore W2255007634C121332964 @default.
- W2255007634 hasConceptScore W2255007634C126322002 @default.
- W2255007634 hasConceptScore W2255007634C141071460 @default.
- W2255007634 hasConceptScore W2255007634C142424586 @default.
- W2255007634 hasConceptScore W2255007634C2776694085 @default.
- W2255007634 hasConceptScore W2255007634C2776755627 @default.
- W2255007634 hasConceptScore W2255007634C2777063308 @default.
- W2255007634 hasConceptScore W2255007634C2777600175 @default.
- W2255007634 hasConceptScore W2255007634C2778119113 @default.
- W2255007634 hasConceptScore W2255007634C2778384902 @default.
- W2255007634 hasConceptScore W2255007634C2778850193 @default.
- W2255007634 hasConceptScore W2255007634C2781413609 @default.
- W2255007634 hasConceptScore W2255007634C29730261 @default.
- W2255007634 hasConceptScore W2255007634C71924100 @default.
- W2255007634 hasConceptScore W2255007634C87355193 @default.
- W2255007634 hasConceptScore W2255007634C90924648 @default.
- W2255007634 hasIssue "4" @default.
- W2255007634 hasLocation W22550076341 @default.
- W2255007634 hasLocation W22550076342 @default.
- W2255007634 hasOpenAccess W2255007634 @default.
- W2255007634 hasPrimaryLocation W22550076341 @default.
- W2255007634 hasRelatedWork W2002669147 @default.
- W2255007634 hasRelatedWork W2018507611 @default.
- W2255007634 hasRelatedWork W2020898191 @default.
- W2255007634 hasRelatedWork W2120828641 @default.
- W2255007634 hasRelatedWork W2121694206 @default.
- W2255007634 hasRelatedWork W2332362313 @default.
- W2255007634 hasRelatedWork W2380296678 @default.
- W2255007634 hasRelatedWork W2393035918 @default.
- W2255007634 hasRelatedWork W280698033 @default.
- W2255007634 hasRelatedWork W2470307162 @default.
- W2255007634 hasVolume "11" @default.
- W2255007634 isParatext "false" @default.
- W2255007634 isRetracted "false" @default.
- W2255007634 magId "2255007634" @default.
- W2255007634 workType "article" @default.